key: cord-0743411-nknqdqgd
authors: Mumoli, Nicola; Vitale, Josè; Mazzone, Antonino
title: Clinical Immunity in Discharged Medical Patients with COVID 19
date: 2020-08-07
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.07.065
sha: 8e7c1808c5cbd71b06f4eac9e329a03975534570
doc_id: 743411
cord_uid: nknqdqgd

• There is no evidence that people who have recovered from COVID-19 are protected from a second infection. • People who have recovered from COVID-19 have antibodies to the virus. • No study has evaluated whether the presence of antibodies to SARS-CoV-2 confers immunity to the infection relapse; • Our clinical observation showed that, at least in the short term, the reinfection is very unlikely and any antibody immunity protects against recurrence.

To face this dilemma with a clinical point of view, we would like to report our preliminary monitoring surveillance based on a large cohort of individuals after they have recovered from COVID-19.

In our prospective, multicenter, cohort study we investigated within three months all adult patients, with confirmed COVID-19, discharged from two Hospitals (Ospedale ASST Ovest Milanese of Legnano and Magenta, Milan, Lombardy), in an area of Italy severely affected by the infection.

Telephone follow-up at 1 and 2 months and clinical contact within 3 months was initiated by health professionals of Hospitals involved. Demographic, clinical, radiologic and laboratory data were recorded in electronic medical records and updated. Local institutional review board approved this study and waived the need for informed consent.

Results: Of 1081 patients involved, 804 (74.3%) were discharged alive and with at least two consecutive negative swab. For all these patients we obtained follow-up data (Table 1 ). In particular we reviewed the signs and symptoms of acute SARS-CoV-2 infection, extending our attention not only to general survey and the respiratory system but also to the skin, the cardio-circulatory system, the gastro-enteric, psychic and nervous apparatus. At 1 and 2 months none has died and none has had any signs of recurrence of infectious at both telephone interview and clinical visit. Twenty-four patients were hospitalized again for acute diseases not closely related to SARS-CoV-2 (Table 1) .

All these patients however were negative at oropharyngeal swab.

We are aware that our follow-up is still short, incomplete and lacking of the immunological data that will be investigated in the next months, but with our clinical observation we think we have confirmed two basic points: the reinfection is very unlikely and any antibody immunity protects against recurrence, at least in the short term.

J o u r n a l P r e -p r o o f

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions

Major Gastrointestinal Bleeding in Anticoagulant therapy, 2 Acute Ischemic Stroke, 2 NSTEMI, 4 Urinary Sepsis, 5 COPD exacerbations, 4 Heart Failure